blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3482750

EP3482750 - NOVEL USE OF SESQUITERPENE DERIVATIVE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  04.08.2023
Database last updated on 29.06.2024
FormerThe patent has been granted
Status updated on  26.08.2022
FormerGrant of patent is intended
Status updated on  13.06.2022
FormerExamination is in progress
Status updated on  29.01.2021
FormerRequest for examination was made
Status updated on  12.04.2019
FormerThe international publication has been made
Status updated on  12.01.2018
Most recent event   Tooltip31.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 03.07.2024 [2024/27]
Applicant(s)For all designated states
Kookmin University Industry Academy Cooperation Foundation
77 Jeongneung-ro
Seongbuk-gu
Seoul 02707 / KR
[2019/20]
Inventor(s)01 / OH, Sangtaek
301-612
88 Jamwon-ro
Seocho-gu
Seoul 06520 / KR
 [2019/20]
Representative(s)V.O.
P.O. Box 87930
Carnegieplein 5
2508 DH Den Haag / NL
[2019/20]
Application number, filing date16908245.014.10.2016
[2019/20]
WO2016KR11558
Priority number, dateKR2016008633107.07.2016         Original published format: KR 20160086331
[2019/20]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018008803
Date:11.01.2018
Language:KO
[2018/02]
Type: A1 Application with search report 
No.:EP3482750
Date:15.05.2019
Language:EN
[2019/20]
Type: B1 Patent specification 
No.:EP3482750
Date:28.09.2022
Language:EN
[2022/39]
Search report(s)International search report - published on:KR11.01.2018
(Supplementary) European search report - dispatched on:EP17.03.2020
ClassificationIPC:A61K31/015, A23L33/10, A61K9/00, A61K9/06, A61P27/02
[2020/16]
CPC:
A23L33/10 (EP,KR,US); A61K31/015 (EP,KR,US); A61K31/423 (US);
A61K31/122 (US); A61K31/136 (US); A61K31/145 (US);
A61K31/196 (US); A61K31/235 (US); A61K31/4184 (US);
A61K9/00 (EP,US); A61K9/0019 (KR); A61K9/0048 (KR);
A61K9/06 (EP,KR,US); A61P27/02 (US); A23V2002/00 (KR,US);
A23V2200/30 (KR) (-)
Former IPC [2019/20]A61K31/015, A23L33/10, A61K9/00, A61K9/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/20]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:NEUARTIGE VERWENDUNG EINES SESQUITERPENDERIVATS[2019/20]
English:NOVEL USE OF SESQUITERPENE DERIVATIVE[2019/20]
French:NOUVELLE UTILISATION D'UN DÉRIVÉ DE SESQUITERPÈNE[2019/20]
Entry into regional phase07.01.2019Translation filed 
07.01.2019National basic fee paid 
07.01.2019Search fee paid 
07.01.2019Designation fee(s) paid 
07.01.2019Examination fee paid 
Examination procedure07.01.2019Examination requested  [2019/20]
05.10.2020Amendment by applicant (claims and/or description)
29.01.2021Despatch of a communication from the examining division (Time limit: M04)
03.06.2021Reply to a communication from the examining division
13.10.2021Despatch of a communication from the examining division (Time limit: M04)
10.02.2022Reply to a communication from the examining division
14.06.2022Communication of intention to grant the patent
18.08.2022Fee for grant paid
18.08.2022Fee for publishing/printing paid
18.08.2022Receipt of the translation of the claim(s)
Opposition(s)29.06.2023No opposition filed within time limit [2023/36]
Fees paidRenewal fee
07.01.2019Renewal fee patent year 03
22.10.2019Renewal fee patent year 04
22.09.2020Renewal fee patent year 05
01.11.2021Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.10.2016
AL28.09.2022
AT28.09.2022
CY28.09.2022
CZ28.09.2022
DK28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
MK28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SI28.09.2022
SK28.09.2022
SM28.09.2022
IE14.10.2022
LU14.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
GB28.12.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
DE03.05.2023
[2024/27]
Former [2024/21]HU14.10.2016
AL28.09.2022
AT28.09.2022
CY28.09.2022
CZ28.09.2022
DK28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SI28.09.2022
SK28.09.2022
SM28.09.2022
IE14.10.2022
LU14.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
GB28.12.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
DE03.05.2023
Former [2024/18]HU14.10.2016
AL28.09.2022
AT28.09.2022
CZ28.09.2022
DK28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SI28.09.2022
SK28.09.2022
SM28.09.2022
IE14.10.2022
LU14.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
GB28.12.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
DE03.05.2023
Former [2023/51]AL28.09.2022
AT28.09.2022
CZ28.09.2022
DK28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SI28.09.2022
SK28.09.2022
SM28.09.2022
IE14.10.2022
LU14.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
GB28.12.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
DE03.05.2023
Former [2023/48]AL28.09.2022
AT28.09.2022
CZ28.09.2022
DK28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SK28.09.2022
SM28.09.2022
IE14.10.2022
LU14.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
GB28.12.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
DE03.05.2023
Former [2023/47]AL28.09.2022
AT28.09.2022
CZ28.09.2022
DK28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SK28.09.2022
SM28.09.2022
LU14.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
GB28.12.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
DE03.05.2023
Former [2023/42]AL28.09.2022
AT28.09.2022
CZ28.09.2022
DK28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SK28.09.2022
SM28.09.2022
LU14.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
DE03.05.2023
Former [2023/35]AL28.09.2022
AT28.09.2022
CZ28.09.2022
DK28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SK28.09.2022
SM28.09.2022
LU14.10.2022
CH31.10.2022
LI31.10.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
DE03.05.2023
Former [2023/34]AL28.09.2022
AT28.09.2022
CZ28.09.2022
DK28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SK28.09.2022
SM28.09.2022
LU14.10.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
Former [2023/30]AL28.09.2022
AT28.09.2022
CZ28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
MC28.09.2022
NL28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SK28.09.2022
SM28.09.2022
LU14.10.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
Former [2023/29]AL28.09.2022
AT28.09.2022
CZ28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SK28.09.2022
SM28.09.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
Former [2023/26]AT28.09.2022
CZ28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
PL28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SK28.09.2022
SM28.09.2022
NO28.12.2022
GR29.12.2022
IS28.01.2023
PT30.01.2023
Former [2023/23]AT28.09.2022
CZ28.09.2022
EE28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SK28.09.2022
SM28.09.2022
NO28.12.2022
GR29.12.2022
PT30.01.2023
Former [2023/22]AT28.09.2022
CZ28.09.2022
FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
RO28.09.2022
RS28.09.2022
SE28.09.2022
SM28.09.2022
NO28.12.2022
GR29.12.2022
PT30.01.2023
Former [2023/20]FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
RS28.09.2022
SE28.09.2022
SM28.09.2022
NO28.12.2022
GR29.12.2022
Former [2023/10]FI28.09.2022
HR28.09.2022
LT28.09.2022
LV28.09.2022
RS28.09.2022
SE28.09.2022
NO28.12.2022
GR29.12.2022
Former [2023/09]FI28.09.2022
LT28.09.2022
LV28.09.2022
RS28.09.2022
SE28.09.2022
NO28.12.2022
Former [2023/08]FI28.09.2022
LT28.09.2022
RS28.09.2022
SE28.09.2022
NO28.12.2022
Documents cited:Search[Y]US2009074795  (FARJO RAFAL A [US]) [Y] 1-13 * abstract * * claim - *;
 [E]KR101692378B  (UNIV KOOKMIN IND ACAD COOP FOUND [KR]) [E] 1-13* the whole document *;
 [E]KR101800346B  (UNIV KOOKMIN IND ACAD COOP FOUND [KR]) [E] 1-13 * the whole document *;
 [Y]  - SEOYOUNG PARK ET AL, "Ilimaquinone and Ethylsmenoquinone, Marine Sponge Metabolites, Suppress the Proliferation of Multiple Myeloma Cells by Down-Regulating the Level of [beta]-Catenin", MARINE DRUGS, (20140528), vol. 12, no. 6, doi:10.3390/md12063231, pages 3231 - 3244, XP055450992 [Y] 1-13 * abstract * * page 3233; figure 1 *

DOI:   http://dx.doi.org/10.3390/md12063231
 [Y]  - IN HYUN HWANG ET AL, "Cytotoxic Activity of Rearranged Drimane Meroterpenoids against Colon Cancer Cells via Down-Regulation of [beta]-Catenin Expression", JOURNAL OF NATURAL PRODUCTS., US, (20150327), vol. 78, no. 3, doi:10.1021/np500843m, ISSN 0163-3864, pages 453 - 461, XP055663856 [Y] 1-13 * abstract * * page 454; figure 1 * * page 456; figure 3 *

DOI:   http://dx.doi.org/10.1021/np500843m
 [Y]  - JOO-HYUN KIM ET AL, "Wnt5a attenuates the pathogenic effects of the Wnt/[beta]-catenin pathway in human retinal pigment epithelial cells via down-regulating [beta]-catenin and Snail", BMB REPORTS, KR, (20150930), vol. 48, no. 9, doi:10.5483/BMBRep.2015.48.9.140, ISSN 1976-6696, pages 525 - 530, XP055663901 [Y] 1-13 * abstract *

DOI:   http://dx.doi.org/10.5483/BMBRep.2015.48.9.140
 [Y]  - CHEN YING ET AL, "Activation of the Wnt Pathway Plays a Pathogenic Role in Diabetic Retinopathy in Humans and Animal Models", AMERICAN JOURNAL OF PATHOLOGY; [10640], ELSEVIER INC, US, (20091201), vol. 175, no. 6, doi:10.2353/AJPATH.2009.080945, ISSN 0002-9440, pages 2676 - 2685, XP009171499 [Y] 1-13 * abstract *

DOI:   http://dx.doi.org/10.2353/ajpath.2009.080945
 [Y]  - GUO XIAOLING ET AL, "Matrigel and Activin A promote cell-cell contact and anti-apoptotic activity in cultured human retinal pigment epithelium cells", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, (20160426), vol. 147, doi:10.1016/J.EXER.2016.04.021, ISSN 0014-4835, pages 37 - 49, XP029579634 [Y] 1-13 * abstract *

DOI:   http://dx.doi.org/10.1016/j.exer.2016.04.021
International search[A]EP0731078  (PHARMA MAR SA [ES]) [A] 1-13* See the entire document. *;
 [A]KR20100051303  (IND ACADEMIC COOP [KR]) [A] 1-13 * See abstract; claims 1-4. *;
 [A]  - PARK, S. et al., "Ilimaquinone and Ethyl Smenoquinone, Marine Sponge Metabolites, Suppress the Proliferation of Multiple Myeloma Cells by Down-regulating the Level of p-catenin", Marine Drugs, (20140000), vol. 12, no. 6, pages 3231 - 3244, XP055450992 [A] 1-13 * See abstract; figure l; page 3233. *

DOI:   http://dx.doi.org/10.3390/md12063231
 [A]  - SENTHILKUMAR, K. et al., "Antiangiogenic Effects of Marine Sponge Derived Compounds on Cancer", Environmental Toxicology and Pharmacology, (20130000), vol. 36, no. 3, pages 1 097 - 1108, XP055450994 [A] 1-13 * See abstract; figure 3. *

DOI:   http://dx.doi.org/10.1016/j.etap.2013.09.014
 [A]  - KONG, D. et al., "Antiproliferative and Anti Angiogenic Activities of Smenospongine, a Marine Sponge Sesquiterpene Aminoquinone", Marine Drugs, (20110000), vol. 9, no. 12, pages 154 - 161, XP055450996 [A] 1-13 * See abstract; figure 1. *

DOI:   http://dx.doi.org/10.3390/md9020154
 [A]  - RIGUERA, R., "Isolating Bioactive Compounds from Marine Organisms", Journal of Marine Biotechnology, (19970000), vol. 5, pages 187 - 193, XP055561610 [A] 1-13 * See the entire document. *
Examination   - HEEBIN SON ET AL, "Stereo-Selective Pharmacokinetics of Ilimaquinone Epimers Extracted from a Marine Sponge in Rats", MARINE DRUGS, CH, (20190301), vol. 17, no. 3, doi:10.3390/md17030171, ISSN 1660-3397, page 171, XP055767374

DOI:   http://dx.doi.org/10.3390/md17030171
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.